

**Register of Genetically Modified Organisms (GMOs)  
Users in Ireland**

<b>The name and address of the notifier</b>	SparingVision 5-7 avenue Percier 75008 Paris
<b>The location (including, where necessary, the name of townland or townlands) of a deliberate release proposed under, or granted consent in accordance with, Part II of the GMO (Deliberate Release) Regulations 2003, S.I. No. 500 of 2003 - Part B release.</b>	Royal Victoria Eye and Ear Hospital Adelaide Road Dublin 2 & Haematology Department Department of Pathology and Laboratory Medicine St. Vincent's University Hospital Elm Park Dublin 4
<b>Notification Ref. No.</b>	B/IE/25/01
<b>GMO Register No.</b>	G0897-02
<b>The date or dates of a deliberate release</b>	September 2025 – March 2032
<b>The description and intended uses of each GMO involved</b>	SPVN20 or AAVi-GIRK1(F137S) is a non-pathogenic recombinant adeno-associated virus (vector) containing an optimized version of the human gene of G protein-gated inwardly rectifying potassium (GIRK) channel 1. The vector has been engineered to target cone photoreceptors following an intravitreal injection.
<b>The purpose of the deliberate release</b>	SPVN20 (orAAVi-GIRK1(F137S)) will be administered to patients with no light perception (NLP) due to advanced rod-cone dystrophy (RCD), and who retain dormant foveal cone photoreceptors (i.e., cells that have lost their ability for phototransduction). The overall objective is to evaluate the safety and tolerability of a single intravitreal injection (IVT) of SPVN20 in subjects with NLP due to RCD.
<b>The date of receipt of a notification or amended notification</b>	13 <sup>th</sup> June 2025
<b>The date of publication of a notice under article 15(1)</b>	
<b>The number of</b>	

**representations, if any,  
received under article 16(1)**

**The date of any request by  
the Agency for further  
information** 15<sup>th</sup> July 2025, 28<sup>th</sup> July 2025, 13<sup>th</sup> August 2025, 01<sup>st</sup>  
September 2025, 9<sup>th</sup> March 2026

**The date of receipt by the  
Agency of any further  
information** 8<sup>th</sup> August 2025, 21<sup>st</sup> August 2025, 10<sup>th</sup> September 2025,  
19<sup>th</sup> March 2026

**The date of receipt, or the  
date on which the Agency  
otherwise became aware, of  
any information or any  
other matter referred to in  
article 22(1)**

**The date of any exercise by  
the Agency of its powers  
under article 22(1)**

**The date and nature of any  
decision by the Commission  
of the European  
Communities under Article  
18 (1) or 23(2) of the  
Directive**

**The date of withdrawal of a  
notification or an amended  
notification**

**The date and nature of the  
decision by the Agency on a  
notification or an amended  
notification** 30<sup>th</sup> September 2025 – Approved  
21<sup>st</sup> October 2025 – Consent Conditions issued  
15<sup>th</sup> April 2026 – Approved  
20<sup>th</sup> April 2026 – Consent Conditions issued